Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug
12:20pm, Tuesday, 12'th Jul 2022
Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.
7 Best Biotech Stocks to Buy in July 2022
07:35am, Friday, 08'th Jul 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. The post 7 Best Biotech Stocks to Buy in July 2022 appeared
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead
11:31am, Wednesday, 06'th Jul 2022 Benzinga
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSY
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
01:32pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
11:56am, Tuesday, 21'st Jun 2022
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year
11:19am, Tuesday, 21'st Jun 2022
U.S.-listed shares of AstraZeneca AZN, +2.98% were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its pri
Ionis Pharma: Too Many Programs Have Failed To Produce Confidence
03:24pm, Wednesday, 15'th Jun 2022
In the last 12 months, I count four Ionis programs that failed. This series of failures does not generate confidence.
Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag
05:00pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.
Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag
02:41pm, Tuesday, 14'th Jun 2022
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.
5 Cathie Wood Stocks to Buy in June
11:00am, Thursday, 09'th Jun 2022
Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation. The post 5 Cathie Wood Stocks to Buy in June appeared first on Inves
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
12:49pm, Friday, 03'rd Jun 2022
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Cathie Wood Is Selling Gene Editing Stocks. Here's Why.
11:45am, Thursday, 02'nd Jun 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Ionis to present at RBC Capital Markets Global Healthcare Conference
07:05am, Thursday, 12'th May 2022
CARLSBAD, Calif. , May 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wedne
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
08:32pm, Monday, 09'th May 2022 Benzinga
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
2
1
1
